Free equity investment tool of Japanese companies

Credit Rating Analysis

Annual

First quarter

Second quarter

Third quarter

Sponsored Link

Related Company

NIPPON PAINT

The Nippon Synthetic Chemical Industry

NIHON NOHYAKU

HISAMITSU PHARMACEUTICAL

Fuso Pharmaceutical Industries

DAIICHI SANKYO

Shin-Etsu Chemical

Nihon Parkrizing

アステラス製薬

塩野義製薬

エスケー化研

ROHTO PHARMACEUTICAL

JSR

関西ペイント

持田製薬

EDIUNET Related Ranking

EDIUNET

EDIUNET Credit Rating

EDIUNET Industry Avg

EDIUNET Prefectures

Yuho! Industry

EDIUNET Rating News

Prev « 2024-04 » Next

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1 -	2 -	3 -	4 -	5 -	6 -	7 -
8 -	9 -	10 -	11 -	12 -	13 -	14 -
15 -	16 -	17 -	18 -	19 -	20 -	21 -
22 -	23 -	24 -	25 -	26 -	27 -	28 -
29 -	30 -

[Update list]

1/28 Retail Trade (CAWACHI:A etc...

1/27 Banks (The Awa Bank:BBB→A)

1/23 Chemicals (Milbon:AA→AAA)

1/21 Glass & Ceramics Products (..

1/21 Machinery (TSUDAKOMA:C)

1/21 Other Services (Netindex.:CC)

1/20 Other Products (Kurogane Kos..

1/20 Wholesale Trade (リーバイ・..

1/20 Other Services (川崎地質:BB→..

1/17 Chemicals (Kawaguchi Chemica..

 RSS

 Company RSS

 Daily RSS

Sponsored Link

Recently Download Chart

クラリオン

クラリオン

クラリオン

クラリオン

メルコホールディングス

Credit Rating Analysis: HISAMITSU PHARMACEUTICAL (Annual )

The details of credit rating (bankruptcy risk) can be checked. A credit rating in nine stages (AAA-C).

【Analysis Menu】 Outline Statement Rating Indicator Download

Sponsored Link

Credit Rating (Bankruptcy Risk): HISAMITSU PHARMACEUTICAL (Annual ) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2013-02-28	A	Credit is high, but affected by biz environs.	¥ 142 B 3.61%	¥ 33 B -1.32%	¥ 18 B 2.00%

Financial Timeline

Date	2013-02-28  (Annual )	2013-05-31  (First quarter )	2013-08-31  (Second quarter )	2013-11-30  (Third quarter )
Credit Rating	A	BBB	A	A
Total Assets	¥ 214 B	¥ 226 B	¥ 245 B	¥ 247 B
Net Assets	¥ 167 B	¥ 178 B	¥ 186 B	¥ 190 B

Financial Statement Risk Analysis: HISAMITSU PHARMACEUTICAL (Annual ) (Consolidated )

Special note

Net sales has increased 4 consecutive terms. The performance is good.

Net Assets have increased 4consecutive terms. The fiscal base is getting better.

[Date: 2013-02-28]  Danger : Warning : Caution : Good

Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (13.17％) is first term Net Profit Margin (13.38％) less , there is a possibility that the profitability has deteriorated.

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -7 B) & Financial Cash Flow (¥ -9 B) is a minus, Operating Cash Flow (¥ 32 B) is a plus,

Dividend
Under the situation of Net Income (¥ 18 B) & Operating Cash Flow (¥ 32 B) , Dividend (¥ -5 B) is paid.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 6 B) is Sales first term ratio (¥ 4 B) more , there is a possibility that the non-performing asset was increased.

[Date: 2012-02-29]  Danger : Warning : Caution : Good

Management Risk (*Net Income is decrease )
Net Income (¥ 18 B) is first term Net Income (¥ 20 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (13.38％) is first term Net Profit Margin (15.28％) less , there is a possibility that the profitability has deteriorated.

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -15 B) & Financial Cash Flow (¥ -13 B) is a minus, Operating Cash Flow (¥ 25 B) is a plus,

Dividend
Under the situation of Net Income (¥ 18 B) & Operating Cash Flow (¥ 25 B) , Dividend (¥ -6 B) is paid.

Financing Risk (*Operating Cash Flow is decrease )
Sales (¥ 137 B) is first term (¥ 137 B) more, however Operating Cash Flow (¥ 25 B) is first term (¥ 36 B) less , there is a possibility that the financing has deteriorated very much.

[Date: 2011-02-28]  Danger : Warning : Caution : Good

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -8 B) & Financial Cash Flow (¥ -15 B) is a minus, Operating Cash Flow (¥ 36 B) is a plus,

Dividend
Under the situation of Net Income (¥ 20 B) & Operating Cash Flow (¥ 36 B) , Dividend (¥ -5 B) is paid.

[Date: 2010-02-28]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 18 B) & Operating Cash Flow (¥ 20 B) , Dividend (¥ -5 B) is paid.

Credit Rating (Bankruptcy Risk): HISAMITSU PHARMACEUTICAL (Annual ) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2013-02-28	AAA	Credit is extremely high. The highest rating.	¥ 122 B 2.60%	¥ 30 B 1.21%	¥ 18 B 10.17%

Financial Timeline

Date	-  (First quarter )	-  (Second quarter )	-  (Third quarter )	2013-02-28  (Annual )
Credit Rating	-	-	-	AAA
Total Assets	-	-	-	¥ 200 B
Net Assets	-	-	-	¥ 168 B

Financial Statement Risk Analysis: HISAMITSU PHARMACEUTICAL (Annual ) (Non-Consolidated )

Special note

Net Assets have increased 4consecutive terms. The fiscal base is getting better.

Cash(¥ 34 B) is more than the total liabilities(¥ 32 B). It is a very steady fiscal base!

[Date: 2013-02-28]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 18 B) & Operating Cash Flow (-) , Dividend (¥ -5 B) is paid.

[Date: 2012-02-29]  Danger : Warning : Caution : Good

Management Risk (*Sales is decrease )
Sales (¥ 119 B) is first term Sales (¥ 120 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Income is decrease )
Net Income (¥ 16 B) is first term Net Income (¥ 20 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (14.05％) is first term Net Profit Margin (17.10％) less , there is a possibility that the profitability has deteriorated.

Dividend
Under the situation of Net Income (¥ 16 B) & Operating Cash Flow (-) , Dividend (¥ -6 B) is paid.

[Date: 2011-02-28]  Danger : Warning : Caution : Good

Management Risk (*Sales is decrease )
Sales (¥ 120 B) is first term Sales (¥ 120 B) less , there is a possibility that the management situation has stagnated and deteriorated

Dividend
Under the situation of Net Income (¥ 20 B) & Operating Cash Flow (-) , Dividend (¥ -5 B) is paid.

[Date: 2010-02-28]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 20 B) & Operating Cash Flow (-) , Dividend (¥ -5 B) is paid.

Related Information: HISAMITSU PHARMACEUTICAL (Annual )

Statement Type

Annual : HISAMITSU PHARMACEUTICAL

First quarter : HISAMITSU PHARMACEUTICAL

Second quarter : HISAMITSU PHARMACEUTICAL

Third quarter : HISAMITSU PHARMACEUTICAL

Analysis Menu

Outline : HISAMITSU PHARMACEUTICAL

Statement : HISAMITSU PHARMACEUTICAL

Rating : HISAMITSU PHARMACEUTICAL

Indicator : HISAMITSU PHARMACEUTICAL

Download : HISAMITSU PHARMACEUTICAL

Industry Comparison Ranking

Chemicals - EDIUNET Industry Rankings

Chemicals - EDIUNET Credit Rating

Chemicals - EDIUNET Industry Avg

Comparison with a neighboring company

Saga - EDIUNET Prefectures

Saga鳥栖市 - EDIUNET Prefectures

Related company's newest statement

Date	Company	Credit Rating	Date
1/23	Milbon	AA→AAA	2013-12-20
1/17	Kawaguchi Chemical Indu..	BBB→BB	2013-11-30
1/17	SANKEI CHEMICAL	A	2013-11-30
1/15	HOKKO CHEMICAL INDUSTRY	BB→B	2013-11-30
1/15	Daito Pharmaceutical Co .	AA	2013-11-30 (Q2)
1/15	KAWAKAMI PAINT MFG.	B→BB	2013-11-30
1/15	旭化学工業	AA	2013-11-30 (Q1)
1/10	OSAKA ORGANIC CHEMICAL ..	BB→BBB	2013-11-30
1/10	HISAMITSU PHARMACEUTICAL	A	2013-11-30 (Q3)
1/10	AMS Life Science	BBB→BB	2013-11-30 (Q1)

EDIUNET Investment News (Chemicals)

1/23 Chemicals (Milbon:AA→AAA)

1/17 Chemicals (Kawaguchi Chemica..

1/15 Chemicals (HOKKO CHEMICAL IN..

1/10 Chemicals (OSAKA ORGANIC CHE..

1/9 Chemicals (SANKO GOSEI:A)

12/27 Chemicals (Niitaka:A)

12/18 Chemicals (KUMIAI CHEMICAL I..

12/12 Chemicals (IHARA CHEMICAL IN..

12/11 Chemicals (Konoshima Chemica..

12/10 Chemicals (NATOCO:AA)

Company Information

Ticker	Market	Industry	Month	report	Rating
HISAMITSU PHARMACEUTICAL	4530	TSE 1st	Chemicals	2	Annual	A

Related Company

Otsuka Holdings (Sales ¥ 1.2 T)

Mitsubishi Tanabe Pharma (Sales ¥ 419 B)

Fuso Pharmaceutical Industries (Sales ¥ 48 B)

ADEKA (Sales ¥ 184 B)

DAIICHI SANKYO (Sales ¥ 997 B)

The Nippon Synthetic Chemical Industry (Sales ¥ 91 B)

Kao (Sales ¥ 1.2 T)

大正製薬ホールディングス (Sales ¥ 285 B)

キョーリン製薬ホールディングス (Sales ¥ 107 B)

塩野義製薬 (Sales ¥ 282 B)

JSR (Sales ¥ 371 B)

NIHON NOHYAKU (Sales ¥ 47 B)

アステラス製薬 (Sales ¥ 1.0 T)

関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .